Project Grant K99HL169746
Award Date
7/1/24
Completion Date
6/30/26
Dollars Obligated
$173K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This $5,187,690 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a research program focused on advancing the understanding of ABO(H) blood group antigens and corresponding anti-ABO(H) antibodies. The program aims to define the factors that govern anti-ABO(H) antibody formation and the specific ABO(H) antigen targets responsible for hemolytic transfusion reactions. The research program involves three distinct projects...
This Project Grant award, valued at $445,708.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to Brigham & Women's Hospital Inc. The award period runs from May 1, 2025 to April 30, 2028. The project aims to define the role of platelet ABO(H) blood group antigens in hemostasis and thrombosis. Specifically, the research will: 1) Investigate the impact of ABO(H) glycans on platelet binding to...
This Project Grant award of $1,149,840.00, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to identify the immunostimulatory ligands on stored red blood cells (RBCs) that trigger alloimmunization in transfusion recipients. The research aims to determine the specific Toll-like receptor (TLR) activation pathways in dendritic cells and B cells that lead to alloantibody production, with...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $344,304 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Trustees of Boston University, doing business as Boston University Medical Campus. The grant will fund a research project titled "A Learning Health System Approach to Improve the Effectiveness of Blood Transfusions During Septic Shock" over a period from August 15, 2024 to July 31, 2029. The project aims to investigate treatment...
This $1,016,449.00 Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports single-cell studies of immune-mediated injury and immunoregulation in human vascular composite allograft (VCA) rejection, with a performance period from August 1, 2024 to July 31, 2027. The award was granted to Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in...
This $1,789,999.00 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports Brigham & Women's Hospital Inc.'s work on a novel approach to increase fetal and embryonic hemoglobins for the treatment of sickle cell anemia. The award period runs from March 1, 2025 to February 29, 2028. Brigham & Women's Hospital Inc. is a prominent academic medical center and research institution...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $167,400 to Brigham & Women's Hospital Inc. to comprehensively investigate how the immune mediator CD70 regulates key endothelial and metabolic pathways related to vascular dysfunction and atherosclerotic cardiovascular disease. The award, effective March 1, 2025 through February 28, 2030, aims to elucidate: 1) CD70 regulation...
This $483,548.00 Project Grant was awarded on August 1, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports "SINGLE-CELL STUDIES OF IMMUNE-MEDIATED INJURY AND IMMUNOREGULATION IN HUMAN VCA REJECTION" at Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston, Massachusetts. The research funded by this grant aims to advance the understanding of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $131,250 to the Vitalant Research Institute (VRI) to investigate the potential for amyloid-beta (Aβ) to be transmitted through blood transfusions, leading to cerebral amyloid angiopathy (CAA) and associated intracerebral hemorrhage. The study aims to (A) assess the prevalence of Aβ pathology markers among blood donors, and (B)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $124,536 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the protective role of B cells in hyperoxic lung injury. The research aims to characterize the dynamics of B cell responses during hyperoxia and examine the protective impacts of B cell supplementation, as well as...